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SUMMARY
I went to the Stanford University Department of Radiology’s three-dimensional （3D） imaging 
laboratory from 1996 to 1999 to study a novel 3D image processing technique using electron beam 
computed tomography （CT）. When I returned to Japan, I found that multi-slice CT had been available 
in daily practice since 1998. We have published a total of 152 peer-reviewed papers on diagnostic images 
in the field of cardiovascular disease. In 2003, when 16-slice CT was available for use in general hospitals, 
we successfully developed a prototype 256-slice cone-beam CT at the National Institute of Radiological 
Sciences. We produced several papers discussing the utilities of this prototype CT in both animal and 
phantom experiments, the concepts and ideas that were currently used for cardiac perfusion and 
myocardium characteristic study. In 2010, our paper was used as a reference in the American College of 
Cardiology Foundation Expert Consensus Guideline. 
The our current topics presented include coronary artery stenosis, coronary arterial plaques, the 
characteristics of the myocardium, the anatomy of structural and congenital heart disease, and the cardiac 
function, all using 16-320 slice CT with reduced radiation exposure in CT acquisition. Furthermore, we are 
now performing novel clinical CT studies combined magnetic resonance imaging （MRI）, positron emission 
tomography, and echocardiography. Using previous image data, we analyzed an epidemiology study using 
CT findings to predict the occurrence of major cardiovascular adverse events over long-term follow-
up periods of more than 100 months （median）, one of the longest follow-up periods documented in the 
literature. We also need to obtain accurate diagnoses for subjects with cardiac failure or fatal arrhythmia of 
unknown origin, allowing them to receive specific effective therapy for their possible cardiac amyloidosis, 
cardiac sarcoidosis, or Fabry’s disease. Of course, in all CT imaging techniques used for evaluation and 
monitoring of cardiovascular risk, we also evaluated the harmful effect of radiation exposure for image 
acquisition. The technology of non-invasive modalities such as CT, echocardiography, or MRI will continue 
to develop; their diagnostic accuracies will increase, and the dose of radiation exposure and amount of 
usage of contrast material by CT will decrease. Finally, I hope to use CT as screening tool for symptomatic 
subjects to identify the occurrence of acute coronary syndromes or fatal ventricular arrhythmia, and hope 
to contribute to improve their prognosis. 
　Key words:  Computed Tomography, Improve Prognosis, Acute coronary syndrome, Coronary Arteries, 
and Myocardium
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Ⅰ．Introduction
 I went to the Stanford University Department of 
Radiology’s three-dimensional （3D） imaging laboratory 
from 1996  to 1999  to study a novel 3D image 
processing technique using electron beam computed 
tomography （CT）. When I returned to Japan, I found 
that multi-slice CT had been available in daily practice 
since 1998. We have published a total of 152 peer 
reviewed papers concern about diagnostic images in 
cardiovascular field. In 2003, when 16-slice CT was 
available for use in general hospitals, we successfully 
developed a prototype 256-slice cone-beam CT at 
the National Institute of Radiological Sciences. We 
produced several papers discussing the utilities of this 
prototype CT in both animal and phantom experiments, 
the concepts and ideas that were currently used for 
cardiac perfusion and myocardium characteristic study.
［References 91,96,98,109,121,136］
 In 2010, our paper was used as a reference in the 
American College of Cardiology Expert Consensus 
Guideline.［Reference 75］. Currently, we have published 
several papers and have presented data at the annual 
meetings of international medical societies （including 
the American Heart Association and American College 
of Cardiology）. The topics presented include coronary 
artery stenosis, coronary arterial plaques, the anatomy of 
structural and congenital heart disease, the characteristics 
of the myocardium, and cardiac function, all using 
16-320 slice CT with reduced radiation exposure in 
CT acquisition. Furthermore, we are now performing 
novel clinical CT studies combined magnetic resonance 
imaging （MRI）, positron emission tomography, and 
echocardiography. Using previous image data, we 
analyzed an epidemiology study using CT findings to 
predict the occurrence of major cardiovascular adverse 
events over long-term follow-up periods of more than 
100 months （median）, one of the longest follow-up 
periods documented in the literature.
 We introduced concretely some of those studies as 
follows.
Ⅱ ．Diagnostic Accuracy of 320-Slice CT for 
Detection of Significant Coronary Artery 
Stenosis in Patients with Various Heart Rates 
and Heart Rhythms Compared with Invasive 
Coronary Angiography （ICA）［Reference 
39］
 To evaluate the diagnostic accuracy of 320 slice 
CT for detection of significant coronary artery stenosis 
in patients with various heart rates （HR） and heart 
rhythms, including tachycardia and chronic atrial 
fibrillation （CAF） （Figure 1） compared with ICA. 
106 consecutive patients underwent both 320 slice 
CT and ICA within 3 months （normal sinus rhythm 
［NSR］ 91.5%, CAF 8.5%, mean HR 65±15 beats/min 
（BPM））. There were no cardiac events between the 2 
procedures. Patients were divided in 2 groups: Group 1 
（HR＜65 with NSR at CT scan, N＝62）, and Group 2 
（HR＞64 with NSR or heart rhythm irregularities at CT 
scan, N＝44）. Patients with ＞50% or ＞75% luminal 
stenosis on CT were compared with those with ＞50% 
or ＞75% stenosis on ICA, respectively. In a segment by 
segment analysis, in all patients, sensitivity, specificity, 
positive （PPV） and negative predictive value （NPV） 
of ＞50% stenosis on CT for predicting ＞50% stenosis 
on ICA were 69, 98, 78, and 97%, respectively, and 
those of ＞75% stenosis on CT for predicting ＞75% 
stenosis on ICA were 78, 98, 64, and 99%, respectively 
（Table 1）. Sensitivity, specificity, PPV, and NPV 
of ＞50% and ＞75% stenosis on CT for predicting 
＞50% and ＞75% stenosis, respectively, on ICA were 
comparable. Diagnostic accuracy was essentially the 
same in both groups. 320 slice CT had high diagnostic 
accuracy for the detection of significant coronary artery 
stenosis compared with ICA. Even though the numbers 
were small, patients with high HR or heart rhythm 
irregularities might have essentially equivalent results to 
those with low HR with NSR. 
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（FP） findings on 320 slice CT compared with ICA 
for detecting coronary arterial stenosis, we followed 
patients with FP findings for occurrence of major 
adverse cardiovascular events （MACE）. 153 patients 
（107 male, 65±12 years） undergoing retrospective 
ECG gated 320 slice CT and ICA within 3 months 
without incident were retrospectively analyzed. We used 
Ⅲ ．False Positive Findings in 320  Slice 
Cardiac CT for Detection of Severe Coronary 
Stenosis in Comparison with ICA Indicate 
Poor Prognosis for Occurrence of MACE
［Reference 4］
 To investigate clinical significance of false positive 
Fig. 1 Typical Images Acquired with 320 Slice Computed Tomography （CT） and by Invasive Coronary Angiography （ICA） 
of a Patient with Chronic Atrial Fibrillation （CAF）. （Modified from Reference 39）.
　A: Typical Image of Coronary Arteries using Enhance 320 Slice CT.
　Curved planar reformation image of the right coronary artery （RCA）.
　After acquiring plural heart beat data, the longest R-to-R interval data was manually selected and data were reconstructed by 
half reconstruction.
　Even though this patient had CAF, there are no banding artifacts and image quality was excellent. There was no significant 
stenosis in any of the vessels on CT.
　B: Images of ICA of the RCA, Acquired from the Same Patient as in Figure 1A. 
　There was also no significant stenosis found on ICA as seen on CT images shown in Figure 1A.
Ａ Ｂ
Table 1　 Diagnostic Accuracy of 320 Slice Computed Tomography （CT） for ＞50% and ＞75% Luminal Stenosis on a 
Segment by Segment, Vessel by Vessel, and Patient by Patient Analysis for Predicting Significant Coronary Artery 
Stenosis of ＞50% and ＞75%, Respectively, on Invasive Coronary Angiography （ICA） in All 106 Patients （Modified 
from Reference 39）.
Sensitivity Speciﬁcity PPV NPV Accuracy
Segment by segment analysis （N＝1481）
＞50% stenosis on CT for ＞50% on ICA 69 （61-77） 98 （97-99） 78 （71-86） 97 （96-98） 96 （95-97） 
＞75% stenosis on CT for ＞75% on ICA 78 （68-89） 98 （98-99） 64 （53-75） 99 （99-100） 97 （97-98） 
Vessel by vessel analysis （N＝407）
＞50% stenosis on CT for ＞50% on ICA 77 （68-86） 94 （91-96） 76 （67-85） 94 （91-96） 90 （87-93）
＞75% stenosis on CT for ＞75% on ICA 83 （72-95） 98 （97-99） 65 （52-78） 98 （97-99） 94 （91-96） 
Patient by patient analysis （N＝106）
＞50% stenosis on CT for ＞50% on ICA 87 （77-96） 82 （71-92） 82 （72-92） 86 （77-96） 84 （77-91） 
＞75% stenosis on CT for ＞75% on ICA 89 （77-99） 87 （79-95） 78 （65-91） 94 （88-100） 88 （81-94） 
　95% confidential intervals are shown within parentheses. PPV and NPV indicate positive and negative predictive values, 
respectively.
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two diagnostic criteria, ＞50% and ＞75% stenosis, 
for both modalities, and followed FP and true negative 
（TN） patients for a median of 20 months. There were 
12 FP and 59 TN patients for ＞50% criterion and 14 
FP and 84 TN patients for ＞75% criterion. Reasons for 
FP were blooming artifact from heavy calcifications, 
non-calcified plaques with outward remodeling, and 
poor image due to tachycardia. During the observation 
period, 1 and 3 patients showed MACE in the FP and 
TN groups, respectively, for ＞50% criterion, and 
5 and 7 patients showed MACE in the FP and TN 
groups, respectively, for ＞75% criterion. Significant 
differences in occurrence of MACE between FP and TN 
groups for ＞75% criterion were observed on Kaplan 
Meier analysis and log rank test （P＝0.015） （Figure 
2）. The most frequent-reason for FP findings of CT 
in comparison with ICA for ＞75% criterion coronary 
arterial stenosis was the blooming artifact due to heavy 
calcifications （71%） （Table 2）. Prognosis for the FP 
group was significantly poorer than TN group, especially 
when FP occurred due to blooming artifact from heavy 
calcifications.
Ⅳ ．Multiple Vulnerable Plaque Characteristic 
Factors Co-existing in Single Non-Obstructive 
Non Calcified or Mixed Plaques in Coronary 
Arteries are Higher Risk Predictors of Major 
Cardiac Events on CT
 To evaluate significance of presence of three 
vulnerable plaque characteristics （VPC） co-existing in 
single non calcified plaques （NCP） or mixed plaques 
（MP） in non obstructed coronary arteries on CT: 1） low 
attenuation （LA） （＜30HU）, 2） positive remodeling 
（PR） and 3） spotty calcification （SC） （Figure 3）, 
for the risk of MACE. 166 consecutive subjects with 
suspected coronary artery disease （81 male; 62±
13 years; hypertension, 61%; diabetes mellitus, 21%; 
dyslipidemia, 56%; smokers, 45%; obese, 49%） 
underwent cardiac CT from 2003 to 2004. On CT no 
significant stenosis （≤ 50%） of coronary arteries was 
observed; subjects were retrospectively followed for 
a median of 103 months after CT and incidence of 
P=0.015
Follow up times (months)
True negative subjects
False positive subjects
Median follow-up: 20 months
Fig. 2 Kaplan Meier Survival Curves for the Occurrence 
of Major Adverse Cardiovascular Events 
（MACE） between Patients with True Negative 
and False Positive Findings for Detecting 
Coronary Arterial Stenosis by Computed 
Tomography （CT） in Comparison with Invasive 
Coronary Angiography （ICA） for the ＞75% 
Stenosis Criterion （Modified from Reference 
39）.
　During a median of 20 months follow-up period, the 
occurrence of MACE was significantly higher in subjects 
with false positive findings than in those with true negative 
findings for the ＞75% stenosis criterion （P＝0.015, log-
rank test）.
Table 2　 Reasons for False Positive Computed Tomography 
（CT） Findings in Detecting Coronary Arterial 
Stenosis for ＞50% and ＞75% Stenosis Criteria 
in Comparison with Corresponding Criterion on 
Invasive Coronary Angiography （ICA） in a Patient 
by Patient Analysis （Modified from Reference 39）.
＞50% Criterion （12 subjects） 
Reasons Lesions （N）
Blooming artifact from heavy calcifications 5
Non calcified plaques with outward remodeling 3
Poor image due to tachycardia 3
Poor imaging due to obesity and aortic valve 
replacement 
1
Overestimation in left circumflex branch lesion 1
＞75% Criterion （14 subjects） 
Reasons Lesions （N）
Blooming artifact from heavy calcifications 10
Non calcified plaques with outward remodeling 2
Poor image due to tachycardia 1
Poor imaging due to obesity 1
Small lesion 2
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MACE was compared. Subjects with old myocardial 
infarction or myocardial diseases were excluded from 
the analysis. MACE included cardiac death, acute 
coronary syndromes, new onset of angina pectoris, 
and cardiac failure. 39 subjects had NCP （17） or MP 
（22）, of whom 8, 29, and 14 subjects had LA, PR, and 
SC in NCP or MP, respectively. These were classified 
into 4 groups, 1） 128 who did not have NCP or MP 
with any VPCs, 2） 20 who had NCP or MP with one 
VPC, 3） 14 who had NCP or MP with two VPCs and 
4） 2 who had NCP or MP with three VPCs. 6 subjects 
（4%） had MACE. Subjects who had NCP or MP 
with ≥ two VPCs （N＝16） had a higher risk of MACE 
than subjects with ≤ one VPC （N＝150） （P＜0.05） 
during the observation period. Significant differences 
between subjects with NCP or MP with ≥ two VPCs 
and others （zero, one VPC groups） were observed at 
each time point when the whole period of follow-up 
was compared by Kaplan Meier analysis and log rank 
test （P＜0.001） （Figure 4）. A Cox proportional hazard 
model revealed that presence of NCP or MP with ≥ two 
VPCs on coronary arteries on CT was a greater predictor 
of MACE （Hazard ratio 7.5, 95% confidential interval 
1.0-55.4, P＜0.05） than other factors. Presence of NCP 
or MP with ≥ two VPCs in non obstructed coronary 
arteries on CT were critical factors for the prediction of 
MACE in subjects with normal myocardium on follow-
up for a median of 103 months. Even in subjects without 
significant stenosis in coronary arteries on CT, if NCP 
or MP with ≥ two VPCs are observed on CT, careful 
follow-up with control of risk factors is desired.
Ⅴ ．Diagnostic Accuracy of Coronary 320 Slice 
CT Angiography Using Retrospective ECG 
Gated Acquisition Compared with Virtual 
Prospective ECG Gated Acquisition with and 
without Padding ［Reference 28］
 To reduce radiation exposure, prospective ECG 
gating without padding is preferable. To evaluate 
diagnostic accuracy of coronary 320  slice CT 
angiography using various acquisition methods, 
we compared retrospective ECG gated with dose 
modulation and “virtual” prospective ECG gating with 
and without padding. We retrospective selected 77 
consecutive symptomatic subjects （52 males, 62±12 
years） with normal sinus rhythm who underwent both 
retrospective ECG gated 320 slice CT and ICA within 3 
months. CT images were reconstructed at 5% from 0 to 
95% of RR interval. Three methods were used to assess 
＞50% coronary stenosis; 1） using only 75% of data 
named virtual prospective ECG gating without padding, 
2） using 70-100% of data if HR was ＜66 BPM, or 
Motoyama S, et al. Circ J. 2007;71:363-6. 
<30HU䋻low attenuated plaque
<5mm2䋻spotty calcification
Lever AW, et al. Am J Cardiol 2003;91:714-718.
Remodeling index
=Area of culprit lesion/Area of 
proximal reference 
Remodeling index ³ 1.05
Kitagawa T, et al. JACC Cardiovasc Imaging. 2009;2:153-60. 
Fig. 3　Definition of Vulnerable Plaque Characteristics.
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Fig. 4 Kaplan-Meier Survival Curves for ≥ 2 Vulnerable 
Plaque Components （VPCs） Observed in a Single 
Non Calcified Plaque （NCP） or Mixed Plaque 
（MP） Simultaneously for Occurrence of MACE.
　Significant differences between the subjects who had a 
single NCP or MP with ≥ 2 VPCs simultaneously and those 
who did not have a single NCP or MP with ≤ 1 VPC were 
seen at each time point and when the whole period of fol-
low up was compared with a Kaplan Meier analysis and log 
rank test （P＜0.001）.
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75% of RR-interval without padding had significantly 
more unevaluable segments than virtual prospective 
ECG gating with padding and retrospective ECG gating 
only in subjects with HR＞65 BPM.
Ⅵ ．Specific Organized Substrates of Ventricular 
Fibrillation: Comparison of 320 Slice CT 
Heart Images in Non-Ischemic Ventricular 
Fibrillation Subjects with Non-Ischemic 
Sustained and Non-Sustained Ventricular 
Tachycardia Subjects ［Reference 35］
 If specific organized substrates of ventricular 
fibrillation （VF） are identified, they may provide 
important information for prevention of sudden cardiac 
death. To identify specific organized substrates of 
VF, we compared 320 slice CT heart images in non 
ischemic VF subjects with non ischemic sustained and 
non sustained ventricular tachycardia （VT） subjects. 
Retrospective analysis of a total of 103 subjects who 
had VF （17 subjects; age, 59±16 years）, sustained VT 
（20 subjects; 62±19 years）, or non-sustained VT （66 
subjects; 60±15 years） underwent 320 slice CT. After using 35-100% of data if HR was ＞65 BPM, named 
virtual prospective ECG gating with padding, and 3） 
using all phase data named retrospective ECG gating. 
In 42-subjects with HR＜66 BPM, there were zero 
unevaluable segments in virtual prospective ECG gating 
with and without padding and retrospective ECG gating. 
But in 35 subjects with HR＞65 BPM, the percentage of 
unevaluable segments was significantly higher in virtual 
prospective ECG gating without padding （13.6±
27.9%） than in virtual prospective ECG gating with 
padding （0.7±3.1%）, and retrospective ECG gating 
（0.7±3.1%） （both P＝0.012） （Figure 5）. Using 
only evaluable-lesions, in 35 subjects with HR＞65 
BPM, sensitivity, specificity, PPV and NPV of CT for 
detecting ＞50% luminal stenosis compared with ICA 
were 82%, 94%, 60%, and 98%, respectively, for virtual 
prospective ECG gating without padding, 97%, 96%, 
73%, and 100%, respectively, for virtual prospective 
ECG gating with padding, and 97%, 96%, 73%, and 
100%, respectively, for retrospective ECG gating （all 
P＝not significant）. Virtual prospective ECG gating at 
Fig. 5 Frequency of Unevaluable Segments of Coronary 
Arteries on Computed Tomography （CT） Among 
Three Electrocardiogram （ECG）-gating Methods
　（Modified from Reference 28）.
　In 35 subjects with heart rate （HR） ＞65 beats per 
minute, the percentage of unevaluable segments of 
coronary arteries among a total of 560 segments on CT 
were significantly higher in virtual prospective ECG gating 
without padding （13.6±27.9%） than in virtual prospective 
ECG gating with padding （0.7±3.1%）, and retrospective 
ECG gating （0.7±3.1%） （both P＝0.012）.
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Fig. 6 Typical 320 Slice Computed Tomographic 
（CT） Images of Myocardial Abnormal Late 
Enhancement （Modified from Reference 35）.
　A 76 year-old male diagnosed as Maron type 2 
hypertrophic cardiomyopathy experienced ventricular 
fibrillation and recovered with use of automated external 
defibrillators. Short axis-enhanced CT images of left 
ventricle （LV） revealed two areas of massive abnormal 
late enhancement （arrows） in interventricular septum. As 
there were contrast defects in the interventricular septum 
in the early phase, late phase acquisition with prospective 
electrocardiogram gating was added and abnormal late 
enhancement was observed, which indicated presence of 
fibrosis. 
　RV; right ventricle.
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subjects who had abnormal late enhancement on CT 
without specific ECG findings. Myocardial abnormal 
late enhancement and fatty change on CT may be 
substrates of VF or sustained VT in non ischemic 
subjects. 320 slice CT can evaluate both coronary 
arteries and myocardium.
Ⅶ ．Clinical Significance of Fat Infiltration in 
the Moderator Band and Right Ventricular 
Myocardium in Multislice CT, and its 
Association with Abnormal Conduction Seen 
in ECG ［Reference 36］
 We evaluated the clinical significance of fat 
infiltration in the moderator band （MB） of the right 
ventricle （RV） and in the RV myocardium （RVM） 
（Figure 8） and its association with conduction 
abnormalities in the electrocardiogram. 132 subjects （58 
male; age 59±27 years） with no findings of organic-
disease （all right and left side hearts were normal） 
undergoing ECG gated non contrast multislice CT 
were retrospectively analyzed for the presence of fat 
excluding 26 ischemic subjects with ＞50% stenosis in 
any coronary arteries on CT, myocardial infarction, or 
coronary vasospastic angina, a total of 77 non ischemic 
subjects （12 VF subjects; age, 58±18 years）, （13 
sustained VT subjects; 55±20 years） or （52 non 
sustained VT subjects; 58±15 years） were analyzed. 
On CT, myocardial abnormal late enhancement （Figure 
6） was significantly more frequent in the VF group 
（75%, all myocardial abnormal late enhancement in left 
ventricle） than in the sustained VT group （31%） and 
the non sustained VT group （35%） （both P＜0.01） 
（Figure 7）. Myocardial fatty change was significantly 
more frequent in the sustained VT group （54%） than 
in the VF group （17%） and the non sustained VT 
group （12%） （both P＜0.01）. Final diagnoses of the 
non ischemic VF and sustained groups included four 
subjects in each case with normal cardiac structure on 
transthoracic echocardiogram; the former included two 
Fig. 7 Comparison of Frequency of Myocardial 
Abnormal Late Enhancement and Fatty Change 
on 320 Slice Computed Tomography （CT） among 
The Three “Non Ischemic” Arrhythmia Groups 
（Ventricular Fibrillation （VF）, Sustained and 
Non Sustained Ventricular Tachycardia （VT）） 
（Modified from Reference 35）. 
　The frequency of myocardial abnormal late enhancement 
on CT was significantly higher in the non ischemic VF 
group （75%, all myocardial abnormal late enhancement was 
in the left ventricular myocardium） than in the non ischemic 
sustained VT group （31%） and the non ischemic non 
sustained VT group （35%） （both P＜0.01）. The frequency 
of myocardial fatty change on CT was significantly higher 
in the non ischemic sustained VT group （54%） than in the 
non ischemic VF group （17%） and the non ischemic non 
sustained VT group （12%） （both P＜0.01）.
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Fat infiltration in the anterior 
free wall in RV myocardium
Fig. 8 Typical Non Enhanced Computed Tomographic 
（CT） Image of Fat Infiltration in the Anterior Free 
wall in the Right Ventricle （RV） Myocardium 
（Modified from Reference 36）.
　Left sagittal image.
　A low CT area can be seen in the anterior free wall in RV 
myocardium. 
　The average CT value was -49HU.
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prognosis. To achieve this purpose, we have to be able to 
predict future occurrence of acute coronary syndromes, 
such as acute myocardial infarction and unstable angina 
pectoris （with fatality rates of approximately 30-40%）, 
in symptomatic patients. We also need to obtain accurate 
diagnoses for subjects with cardiac failure or fatal 
arrhythmia of unknown origin, allowing them to receive 
specific effective therapy for their possible cardiac 
amyloidosis, cardiac sarcoidosis, or Fabry’s disease.
 We must first accurately identify patients with 
asymptomatic coronary artery disease using CT, finding 
those who have coronary arterial plaques in which 
vulnerable components such as positive remodeling, 
low CT attenuation, and spotty calcification exist, but 
luminal stenosis is absent. Next, we have to confirm 
through large-scale, long-term prospective epidemiology 
study whether these patients would actually experience 
acute coronary syndrome. And finally, when we find 
these vulnerable patients, we need to identify what 
procedures will improve their future prognosis; these 
procedures could include modification of coronary risk 
factors, prescription of low-dose aspirin, statin, or beta 
blocker, or even percutaneous coronary intervention as 
the preventive therapy.
 For myocardial disease with fatal ventricular 
arrhythmia, we speculated that presence of myocardial 
fibrosis detected by CT or MRI may have a relationship 
with the occurrence of fatal ventricular arrhythmia. If 
we detect myocardial fibrosis, we have advocated that 
we should be concerned about possible fatal ventricular 
arrhythmia, evaluating the patients with 24-hour 
monitored or Holter electrocardiography.
 Of course, in all CT imaging techniques used for 
evaluation and monitoring of cardiovascular risk, we 
should be aware of the harmful effect of radiation 
exposure and renal dysfunction due to use of contrast 
materials for image acquisition. We must weigh the 
merits of cardiac CT acquisition to detect vulnerable 
or symptomatic patients, or myocardial fibrosis; if 
preventive therapy is useful in producing reliable 
evidence of disease, the merits will overcome the risk 
of radiation exposure and possible reactions to contrast 
material.
infiltrating the MB or RVM. MB fat infiltration was 
detected in 42 subjects, but these individuals showed no 
significant differences in the incidence of right bundle 
branch block, mean QRS width or standard-deviation of 
the QRS axis, which would have suggested the presence 
of hemi left bundle branch block. Only age （64.3 vs 
57.9 years, P＝0.025） was significantly different in 
subjects with MB fat infiltration. But logistic regression 
showed none of the factor associated with increased 
presence of MB fat infiltration. RVM fat infiltration 
was detected in 35 subjects, again with no significant 
differences in the incidence of right bundle branch block, 
QRS width or standard-deviation of the QRS axis. 
Only age （65.9 vs 57.8 years, P＝0.001） and gender 
（71% vs 51% female, P＝0.033） were significantly 
different in subjects with RVM fat infiltration. Logistic 
regression showed age （Odd ratio＝1.05 and 95% CI
＝1.01～1.08 P＝0.008） and female sex （Odd ratio
＝2.44 and 95% CI＝1.03～5.88; P＝0.043） were 
associated with increased RV fat infiltration （Table 3）. 
MB or RVM fat infiltration seen on CT may not indicate 
organized abnormal myocardial conduction, but RVM 
fat infiltration may indicate only degeneration due to 
aging, especially in females.
Ⅷ．Conclusions
 Our final purpose in using CT data is to establish 
a new preventive medical system to improve patient 
Table 3　 A Logistic Regression Model Taking the Presence 
of Fat Infiltration in the Right Ventricle Myocardium 
as the Dependent Variable, and Age, Female Sex, 
Hypertension, Diabetes Mellitus and Hyperlipidemia 
as the Predictor Variables （Modified from Reference 
36）. 
Odds ratio 
95% confidence 
interval  
P value
Age 1.05 1.01～1.08 0.01
Female sex 2.44 1.03～5.88 0.04
Hypertension 0.57 0.23～1.42 0.23
Diabetes mellitus 1.74 0.45～6.70 0.42
Hyperlipidemia 1.32 0.57～3.05 0.52
　Age and female sex were associated with increased fat 
infiltration in the right ventricular myocardium （Odd ratio 
and 95% confidence interval, 1.05 with 1.01～1.08, P ＝
0.008, and 2.44 with 1.03～5.88, P＝0.043, respectively）.
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 The technology of non-invasive modalities such as 
CT, echocardiography, or MRI will continue to develop; 
their diagnostic accuracies will increase, and the dose 
of radiation exposure and amount of usage of contrast 
material by CT will decrease.
 Finally, I hope to use CT as screening tool for 
symptomatic subjects to identify the occurrence of acute 
coronary syndromes or fatal ventricular arrhythmia, 
and hope to contribute to improve their prognosis. 
Furthermore, as a result of improved prognosis using 
this technology, we may be able to reduce medical 
expenses worldwide.
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